These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36624932)

  • 1. In vivo overexpression of synaptogyrin-3 promotes striatal synaptic dopamine uptake in LRRK2
    Ho PW; Li L; Liu HF; Choi ZY; Chang EES; Pang SY; Malki Y; Leung CT; Kung MH; Ramsden DB; Ho SL
    Brain Behav; 2023 Feb; 13(2):e2886. PubMed ID: 36624932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional Regulation of the Synaptic Vesicle Protein Synaptogyrin-3 (
    Li L; Ho PW; Liu H; Pang SY; Chang EE; Choi ZY; Malki Y; Kung MH; Ramsden DB; Ho SL
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRRK2 R1441G mice are more liable to dopamine depletion and locomotor inactivity.
    Liu HF; Lu S; Ho PW; Tse HM; Pang SY; Kung MH; Ho JW; Ramsden DB; Zhou ZJ; Ho SL
    Ann Clin Transl Neurol; 2014 Mar; 1(3):199-208. PubMed ID: 25356398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
    Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
    J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
    Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
    Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
    Chen ML; Wu RM
    J Biomed Sci; 2022 Aug; 29(1):60. PubMed ID: 35965315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson's disease.
    Liu HF; Ho PW; Leung GC; Lam CS; Pang SY; Li L; Kung MH; Ramsden DB; Ho SL
    Sci Rep; 2017 Jan; 7():40887. PubMed ID: 28098219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.
    Longo F; Mercatelli D; Novello S; Arcuri L; Brugnoli A; Vincenzi F; Russo I; Berti G; Mabrouk OS; Kennedy RT; Shimshek DR; Varani K; Bubacco L; Greggio E; Morari M
    Acta Neuropathol Commun; 2017 Mar; 5(1):22. PubMed ID: 28292328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
    Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
    Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
    Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
    Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging.
    Chen X; Xie C; Tian W; Sun L; Zheng W; Hawes S; Chang L; Kung J; Ding J; Chen S; Le W; Cai H
    Mol Neurodegener; 2020 Feb; 15(1):12. PubMed ID: 32075681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's Disease-Linked LRRK2-G2019S Mutation Alters Synaptic Plasticity and Promotes Resilience to Chronic Social Stress in Young Adulthood.
    Matikainen-Ankney BA; Kezunovic N; Menard C; Flanigan ME; Zhong Y; Russo SJ; Benson DL; Huntley GW
    J Neurosci; 2018 Nov; 38(45):9700-9711. PubMed ID: 30249796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
    Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
    J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2-G2019S mice display alterations in glutamatergic synaptic transmission in midbrain dopamine neurons.
    Skiteva O; Yao N; Sitzia G; Chergui K
    J Neurochem; 2022 Apr; 161(2):158-172. PubMed ID: 35152441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease.
    Nguyen M; Krainc D
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5576-5581. PubMed ID: 29735704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.